Gapping down
In reaction to disappointing earnings/guidance: EZCH -6.4%, .
M&A news: HRB -6.1% (announced that the regulatory approval process regarding its purchase and assumption agreement with BofI Federal (BOFI) will not be complete this calendar year).
Select oil/gas related names showing early weakness: TOT -0.9%, STO -0.8%, RDS.A -0.4%.
Other news: SNSS -62.7% (announces results from pivotal Phase 3 VALOR trial of Vosaroxin and Cytarabine; trial does not reach primary endpoint), ADHD -43.3% (announces topline results from Phase III study of MDX in adult ADHD), EMITF -5.7% (announces that InSightec received HCSC positive coverage decision for its ExAblate procedure for pain palliation of bone cancer metastases),RSH -5.1% (agrees to restructure a portion of its existing debt, providing additional near-term liquidity), MU -1.2% (still checking).
Analyst comments: TKMR -7.2% (downgraded to Mkt Perform from Outperform at Leerink Partners), FTNT -2.3% (downgraded to Equal-Weight from Overweight at Morgan Stanley), QLIK -2.1% (downgraded to Equal-Weight from Overweight at Morgan Stanley), PTCT -1.5% (downgraded to Mkt Perform from Outperform at Cowen), CL -1.3% (downgraded to Equal Weight from Overweight at Barclays), MBLY -0.8% (downgraded to Mkt Perform from Outperform at Raymond James), DECK -0.8% (downgraded to Neutral from Overweight at Piper Jaffray), BWLD -0.6% (downgraded to Neutral from Outperform at Wedbush), MCD -0.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley).
In reaction to disappointing earnings/guidance: EZCH -6.4%, .
M&A news: HRB -6.1% (announced that the regulatory approval process regarding its purchase and assumption agreement with BofI Federal (BOFI) will not be complete this calendar year).
Select oil/gas related names showing early weakness: TOT -0.9%, STO -0.8%, RDS.A -0.4%.
Other news: SNSS -62.7% (announces results from pivotal Phase 3 VALOR trial of Vosaroxin and Cytarabine; trial does not reach primary endpoint), ADHD -43.3% (announces topline results from Phase III study of MDX in adult ADHD), EMITF -5.7% (announces that InSightec received HCSC positive coverage decision for its ExAblate procedure for pain palliation of bone cancer metastases),RSH -5.1% (agrees to restructure a portion of its existing debt, providing additional near-term liquidity), MU -1.2% (still checking).
Analyst comments: TKMR -7.2% (downgraded to Mkt Perform from Outperform at Leerink Partners), FTNT -2.3% (downgraded to Equal-Weight from Overweight at Morgan Stanley), QLIK -2.1% (downgraded to Equal-Weight from Overweight at Morgan Stanley), PTCT -1.5% (downgraded to Mkt Perform from Outperform at Cowen), CL -1.3% (downgraded to Equal Weight from Overweight at Barclays), MBLY -0.8% (downgraded to Mkt Perform from Outperform at Raymond James), DECK -0.8% (downgraded to Neutral from Overweight at Piper Jaffray), BWLD -0.6% (downgraded to Neutral from Outperform at Wedbush), MCD -0.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley).